SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

Inclusion Criteria:

- Documented informed consent of the participant

- Age >=18 years

- Eastern Cooperative Oncology Group (ECOG) =<1

- Allogeneic or autologous hematopoietic cell transplant (HCT), cellular therapy
(chimeric antigen receptor [CAR] T-cell) recipients who are at >= 3 months of
infusion date of respective regimen

- Platelets >= 50,000/mm^3 (to be performed within 30 days prior to day 0 of protocol
therapy unless otherwise stated)

- White blood cells (WBCs) >= 1000/mm^3 (to be performed within 30 days prior to day 0
of protocol therapy unless otherwise stated)

- Total bilirubin < 1.5 X upper limit of normal (ULN) (to be performed within 30 days
prior to day 0 of protocol therapy unless otherwise stated)

- Aspartate aminotransferase (AST) < 2.5 X ULN (to be performed within 30 days prior
to day 0 of protocol therapy unless otherwise stated)

- Alanine aminotransferase (ALT) < 2.5 X ULN (to be performed within 30 days prior to
day 0 of protocol therapy unless otherwise stated)

- Creatinine < 1.5 X ULN (to be performed within 30 days prior to day 0 of protocol
therapy unless otherwise stated)

- Negative COVID-19 PCR test

- Women of childbearing potential (WOCBP): negative urine or serum pregnancy test (to
be performed within 30 days prior to day 0 of protocol therapy unless otherwise
stated). If the urine pregnancy test is inconclusive a serum pregnancy test will be
required

- Agreement by females and males of childbearing potential* to use an effective method
of birth control or abstain from heterosexual activity for the course of the study
through at least 6 weeks after the last dose of protocol therapy

- Childbearing potential defined as not being surgically sterilized (men and
women) or have not been free from menses for > 1 year (women only)

Exclusion Criteria:

- Systemic corticosteroids required for chronic conditions at doses > 0.5mg/kg/day
prednisone equivalent within 7 days of enrollment

- Prior Evusheld or other anti-SARS CoV-2 prophylaxis < 2 weeks prior to enrollment

- Therapies that cause profound T-cell or B cell depletion within 30 days of
enrollment

- Maintenance therapies (e.g. rituximab, Bruton tyrosine kinase inhibitors, Janus
kinase inhibitors) within 30 days of enrollment

- Received investigational or licensed SARS-CoV-2 vaccines after their qualifying
cellular therapy. Patients who received a SARS- CoV-2 vaccine prior to cellular
therapy are eligible for this trial, as revaccination for these patients (e.g. flu
and shingles vaccine) is standard of care.

- Received a live vaccine ≤30 days prior to administration of study vaccine or
subjects who are =< 2 weeks within administration of inactivated vaccines (e.g.
influenza vaccine). Flu shots are allowed > 2 weeks before the first injection and >
2 weeks post 2nd injection

- History of allergic reactions attributed to compounds of similar chemical or
biologic composition to vaccine agents

- History of adverse event with a prior smallpox vaccination

- Any MVA vaccine or poxvirus vaccine in the last 12 months

- History (suspected or confirmed) of myocarditis or pericarditis

- Clinically significant uncontrolled illness

- Females only: Pregnant or breastfeeding

- Any other condition that would, in the Investigator's judgment, contraindicate the
subject's participation in the clinical study due to safety concerns with clinical
study procedures

- Prospective participants who, in the opinion of the investigator, may not be able to
comply with all study procedures (including compliance issues related to
feasibility/logistics)

- Anyone considered to be in a vulnerable population as defined in 45 CFR §46.111
(a)(3) and 45 CFR §46, Subparts B-D